瘤内放射增强纳米颗粒NBTXR3联合放疗治疗头颈癌:1期剂量扩展非随机临床试验
这项单臂1期剂量扩展试验在20个欧洲中心纳入56例无法接受顺铂或西妥昔单抗的局部晚期头颈鳞癌患者,给予瘤内NBTXR3(22%估计肿瘤体积)后放疗70 Gy/35次。NBTXR3相关不良事件发生率16%,3级以上11%;可评估患者中注射原发灶客观缓解率82%,全部病灶80%,中位无进展生存11.4个月,中位总生存18.1个月。
要点
- 无法接受顺铂或西妥昔单抗的局部晚期HNSCC患者可考虑瘤内NBTXR3联合放疗。
- NBTXR3相关3级以上不良事件11%,最常见为口腔炎(4%)。
- 可评估患者注射原发灶ORR 82%,全部病灶ORR 80%。
核心结论
- 瘤内NBTXR3联合放疗在无法接受顺铂或西妥昔单抗的高危局部晚期HNSCC患者中可行,并显示初步疗效信号。
研究设计与样本
- 单臂1期剂量扩展非随机临床试验,2019年3月4日至2022年1月10日在欧洲20个中心开展,共治疗56例患者。
- 纳入研究者判断不适合顺铂和西妥昔单抗、不可切除T3-4或III/IVA期口腔或口咽HNSCC患者。
- 干预为原发肿瘤单次瘤内注射NBTXR3(推荐剂量为估计肿瘤体积的22%),随后放疗70 Gy/35次。
主要发现
- 56例患者中位年龄72岁(范围44-89),男性40例(71%),70岁及以上34例(61%),年龄校正Charlson合并症指数≥4者36例(64%)。
- NBTXR3相关治疗中出现的不良事件发生于9例(16%),其中6例(11%)为3级及以上,最常见为口腔炎2例(4%)。
- 44例可评估患者中,注射原发肿瘤ORR为82%(95% CI 67-92),全部病灶ORR为80%(95% CI 65-90)。
- 全部56例治疗患者中,中位无进展生存期11.4个月(95% CI 6.7至未达到),中位总生存期18.1个月(95% CI 9.7至未达到)。
- 中位随访33.0个月(范围0.7-44.6)。
临床怎么用
- 对于无法接受顺铂或西妥昔单抗的局部晚期HNSCC患者,瘤内NBTXR3联合放疗可作为探索性治疗选择。
- 治疗期间需关注NBTXR3相关不良事件,尤其是口腔炎等3级及以上毒性。
局限性
- 单臂非随机设计,无对照组。
- 12例患者未能完成放疗或缺乏治疗后肿瘤评估,疗效分析仅基于44例可评估患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intratumoral delivery of NBTXR3 radioenhancer followed by radiation therapy (RT) previously demonstrated safety and feasibility in cisplatin-ineligible and cetuximab-ineligible patients with locally advanced head and neck squamous cell carcinoma (HNSCC) in a dose-escalation phase 1 study. OBJECTIVE: To evaluate safety and preliminary efficacy of NBTXR3 followed by RT in patients with locally advanced HNSCC ineligible to receive concurrent systemic therapy. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, phase 1 dose-expansion nonrandomized clinical trial was conducted across 20 centers in Europe between March 4, 2019, and January 10, 2022. Patients were ineligible for cisplatin and cetuximab per investigator's judgement and had unresectable T3-4 or overall stage III/IVA HNSCC (per the American Joint Committee on Cancer Staging Manual, eighth edition) of the oral cavity or oropharynx. Data were analyzed from July to August 2023. INTERVENTIONS: Patients received a single intratumoral administration of NBTXR3 in the primary tumor at the recommended dose of 22% of estimated tumor volume (ETV) followed by RT (70 Gy over 35 fractions). MAIN OUTCOMES AND MEASURES: Primary outcomes were safety and efficacy assessed by the objective response rate (ORR) of the NBTXR3-injected primary tumor. Other outcomes included ORR of all lesions (injected primary tumor and noninjected involved lymph nodes), progression-free survival, and overall survival. RESULTS: Of the 56 patients treated, the median (range) age was 72 (44-89) years, 40 (71%) were men, 34 (61%) were 70 years and older, and 36 (64%) had a substantial burden of comorbidities (age-adjusted Charlson Comorbidity Index score of 4 or greater). Median (range) follow-up was 33.0 (0.7-44.6) months. NBTXR3-related treatment-emergent adverse events occurred in 9 patients (16%), of which 6 (11%) were grade 3 or higher, the most frequent being stomatitis (2 [4%]). Objective tumor response was assessed in 44 patients, as 12 patients were unable to complete RT or did not have posttreatment tumor assessment. In this evaluable patient population, the ORR of the injected primary tumor and ORR of all lesions were 82% (95% CI, 67-92) and 80% (95% CI, 65-90), respectively. Among all 56 treated patients, the median progression-free survival was 11.4 months (95% CI, 6.7 to not reached), and the median overall survival was 18.1 months (95% CI, 9.7 to not reached). CONCLUSIONS AND RELEVANCE: This dose-expansion phase 1 nonrandomized clinical trial demonstrated that intratumoral NBTXR3 followed by RT in a high-risk patient population unable to receive cisplatin or cetuximab was feasible and had a preliminary efficacy signal that supports a benefit-risk profile being evaluated in an ongoing randomized phase III trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01946867.
引用
- Le Tourneau C, Liem X, Nguyen F, et al. Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41609775. doi:10.1001/jamaoto.2025.4939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。